Publications by authors named "Lindsay Wieczorek"

Article Synopsis
  • Nearly all transmitted HIV-1 cases are CCR5 (R5)-tropic, but this research identifies a case of CXCR4 (X4)-tropic HIV-1 in a participant from the RV217 cohort, highlighting its transmissibility.
  • The X4 HIV-1 caused faster depletion of CD4 T cells compared to R5 infections, affecting naive and central memory CD4 subsets more severely, while showing resistance to certain broadly neutralizing antibodies (bNAbs).
  • This study suggests that X4-tropic HIV-1 can be transmitted among individuals with a normal CCR5 gene, indicating that the specific tropism of HIV-1 could influence its transmission potential and
View Article and Find Full Text PDF

The current study analyzed the intersecting biophysical, biochemical, and functional properties of extracellular particles (EPs) with the human immunodeficiency virus type-1 (HIV-1) beyond the currently accepted size range for HIV-1. We isolated five fractions (Frac-A through Frac-E) from HIV-infected cells by sequential differential ultracentrifugation (DUC). All fractions showed a heterogeneous size distribution with median particle sizes greater than 100 nm for Frac-A through Frac-D but not for Frac-E, which contained small EPs with an average size well below 50 nm.

View Article and Find Full Text PDF

The magnitude of the HIV-1 epidemic in Nigeria is second only to the subtype C epidemic in South Africa, yet the subtypes prevalent in Nigeria require further characterization. A panel of 50 subtype G and 18 CRF02_AG Nigerian HIV-1 pseudoviruses (PSV) was developed and envelope coreceptor usage, neutralization sensitivity and cross-clade reactivity were characterized. These PSV were neutralized by some antibodies targeting major neutralizing determinants, but potentially important differences were observed in specific sensitivities (eg.

View Article and Find Full Text PDF

An effective HIV-1 vaccine must elicit broadly neutralizing antibodies (bnAbs) against highly diverse Envelope glycoproteins (Env). Since Env with the longest hypervariable (HV) loops is more resistant to the cognate bnAbs than Env with shorter HV loops, we redesigned hypervariable loops for updated Env consensus sequences of subtypes B and C and CRF01_AE. Using modeling with AlphaFold2, we reduced the length of V1, V2, and V5 HV loops while maintaining the integrity of the Env structure and glycan shield, and modified the V4 HV loop.

View Article and Find Full Text PDF

The RV144 Thai phase III clinical trial's canarypox-protein HIV vaccine regimen showed modest efficacy in reducing infection. We therefore sought to determine the effects of vaccine administration on innate cell activation and subsequent associations with vaccine-induced immune responses. RV306 was a randomized, double-blind clinical trial in HIV-uninfected Thai adults that tested delayed boosting following the RV144 regimen.

View Article and Find Full Text PDF
Article Synopsis
  • The emergence of SARS-CoV-2 variants with reduced vaccine effectiveness shows the need for new vaccine designs that provide wider protection.
  • This study evaluates the antibody response from a novel vaccine, the Spike Ferritin Nanoparticle (SpFN), in non-human primates, particularly focusing on the antibodies that target different regions of the virus's Spike protein.
  • Six potent neutralizing antibodies were identified, demonstrating broad effectiveness against various sarbecovirus variants, including Delta and Omicron, with one antibody showing strong protection in murine studies.
View Article and Find Full Text PDF

Given the continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VoCs), immunotherapeutics that target conserved epitopes on the spike (S) glycoprotein have therapeutic advantages. Here, we report the crystal structure of the SARS-CoV-2 S receptor-binding domain (RBD) at 1.95 Å and describe flexibility and distinct conformations of the angiotensin-converting enzyme 2 (ACE2)-binding site.

View Article and Find Full Text PDF

Subtype B HIV-1 has been the primary driver of the HIV-1 epidemic in the United States (U.S.) for over forty years and is also a prominent subtype in the Americas, Europe, Australia, the Middle East and North Africa.

View Article and Find Full Text PDF

Background: The CCR5 (R5) to CXCR4 (X4) coreceptor switch in natural HIV-1 infection is associated with faster progression to AIDS, but the mechanisms remain unclear. The difficulty in elucidating the evolutionary origin of the earliest X4 viruses limits our understanding of this phenomenon.

Methods: We tracked the evolution of the transmitted/founder (T/F) HIV-1 in RV217 participants identified in acute infection.

View Article and Find Full Text PDF

Nearly all transmitted/founder (T/F) HIV-1 are CCR5 (R5)-tropic. While previous evidence suggested that CXCR4 (X4)-tropic HIV-1 are transmissible, detection was not at the earliest stages of acute infection. Here, we identified an X4-tropic T/F HIV-1 in a participant in acute infection cohort.

View Article and Find Full Text PDF

Nearly all transmitted/founder (T/F) HIV-1 are CCR5 (R5)-tropic. While previous evidence suggested that CXCR4 (X4)-tropic HIV-1 are transmissible, detection was not at the earliest stages of acute infection. Here, we identified an X4-tropic T/F HIV-1 in a participant in acute infection cohort.

View Article and Find Full Text PDF
Article Synopsis
  • Novel monoclonal antibodies (MAbs) need to effectively neutralize various sarbecoviruses and adapt to new variants of SARS-CoV-2, with a focus on the class V epitope for broader protection.
  • The crystal structure of the SARS-CoV-2 receptor binding domain (RBD) in complex with the MAb WRAIR-2063 reveals its ability to target a conserved region, effectively binding to multiple variants and highlighting its potential as a universal therapeutic option.
  • This research on MAbs from vaccination or natural infection provides important insights into their role in combating COVID-19, suggesting the class V epitope could be a key target for developing future vaccines and therapies against related viruses.
View Article and Find Full Text PDF

The RV144 phase III vaccine trial demonstrated that ALVAC-HIV and AIDSVAX B/E administration over 6 months resulted in 31% efficacy in preventing HIV acquisition, while administration of AIDSVAX B/E alone in both VAX003 and VAX004 studies failed to show efficacy. In this study, we aimed to understand the impact of ALVAC-HIV on the development of cellular, humoral, and functional immune responses compared to the administration of AIDSVAX B/E alone. ALVAC-HIV in combination with 3 doses of AIDSVAX B/E significantly increased CD4+ HIV-specific T cell responses, polyfunctionality, and proliferation compared with 3 doses of AIDSVAX B/E alone.

View Article and Find Full Text PDF

Introduction: Antibody therapeutic strategies have served an important role during the COVID-19 pandemic, even as their effectiveness has waned with the emergence of escape variants. Here we sought to determine the concentration of convalescent immunoglobulin required to protect against disease from SARS-CoV-2 in a Syrian golden hamster model.

Methods: Total IgG and IgM were isolated from plasma of SARS-CoV-2 convalescent donors.

View Article and Find Full Text PDF

Understanding the dynamics of early immune responses to HIV-1 infection, including the evolution of initial neutralizing and antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies, will inform HIV vaccine design. In this study, we assess the development of autologous neutralizing antibodies (ANAbs) against founder envelopes (Envs) from 18 participants with HIV-1 CRF01_AE acute infection. The timing of ANAb development directly associated with the magnitude of the longitudinal ANAb response.

View Article and Find Full Text PDF

Despite rapid and ongoing vaccine and therapeutic development, SARS-CoV-2 continues to evolve and evade, presenting a need for next-generation diverse therapeutic modalities. Here we show that nurse sharks immunized with SARS-CoV-2 recombinant receptor binding domain (RBD), RBD-ferritin (RFN), or spike protein ferritin nanoparticle (SpFN) immunogens elicit a set of new antigen receptor antibody (IgNAR) molecules that target two non-overlapping conserved epitopes on the spike RBD. Representative shark antibody variable NAR-Fc chimeras (ShAbs) targeting either of the two epitopes mediate cell-effector functions, with high affinity to all SARS-CoV-2 viral variants of concern, including the divergent Omicron strains.

View Article and Find Full Text PDF

The CCR5 (R5) to CXCR4 (X4) coreceptor switch in natural HIV-1 infection is associated with faster progression to AIDS, but the underlying mechanisms remain unclear. The difficulty in capturing the earliest moment of coreceptor switch limits our understanding of this phenomenon. Here, by tracking the evolution of the transmitted/founder (T/F) HIV-1 in a prospective cohort of individuals at risk for HIV-1 infection identified very early in acute infection, we investigated this process with high resolution.

View Article and Find Full Text PDF

Fc-mediated virus entry has been observed for many viruses, but the characterization of this activity in convalescent plasma against SARS-CoV-2 Variants of Concern (VOC) is undefined. In this study, we evaluated Fc-mediated viral entry (FVE) on FcγRIIa-expressing HEK293 cells in the presence of SARS-CoV-2 convalescent plasma and compared it with SARS-CoV-2 pseudovirus neutralization using ACE2-expressing HEK293 cells. The plasma were collected early in the pandemic from 39 individuals.

View Article and Find Full Text PDF

The need for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) next-generation vaccines has been highlighted by the rise of variants of concern (VoCs) and the long-term threat of emerging coronaviruses. Here, we design and characterize four categories of engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of the prefusion SARS-CoV-2 spike (S), S1, and receptor-binding domain (RBD). These immunogens induce robust S binding, ACE2 inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2.

View Article and Find Full Text PDF

Early initiation of antiretroviral therapy (ART) in acute HIV infection (AHI) is effective at limiting seeding of the HIV viral reservoir, but little is known about how the resultant decreased antigen load affects long-term Ab development after ART. We report here that Env-specific plasma antibody (Ab) levels and Ab-dependent cellular cytotoxicity (ADCC) increased during the first 24 weeks of ART and correlated with Ab levels persisting after 48 weeks of ART. Participants treated in AHI stage 1 had lower Env-specific Ab levels and ADCC activity on ART than did those treated later.

View Article and Find Full Text PDF
Article Synopsis
  • Researchers are investigating therapeutic monoclonal antibodies (mAbs) targeting different vulnerable sites on the SARS-CoV-2 spike protein to prevent the virus from escaping treatment and to enhance protection against variants.
  • They discovered several effective neutralizing antibodies that can be used in combination, showing strong protection in a mouse model of infection.
  • One specific RBD antibody, WRAIR-2125, was particularly effective against all major variants and, when used with other mAbs, helped prevent the virus from evading the immune response.
View Article and Find Full Text PDF

The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the Alpha (B.1.

View Article and Find Full Text PDF

The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the B.1.

View Article and Find Full Text PDF
Article Synopsis
  • The need for next-generation SARS-CoV-2 vaccines is driven by the emergence of new variants and long-term coronavirus risks, leading to the creation of four types of engineered nanoparticle immunogens that mimic key parts of the virus.
  • These immunogens successfully stimulated strong antibody responses in mice, with one type, the Spike-ferritin nanoparticle (SpFN), producing significantly higher neutralizing antibody levels after just one shot compared to convalescent serum.
  • Immunizations with SpFN and another type, RBD-Ferritin nanoparticle (RFN), provided protection in mice against lethal SARS-CoV-2 infections and generated potent neutralizing antibodies against
View Article and Find Full Text PDF